Glycostem CMO Kai Pinkernell and CDO Volker Huppert are going to attend the Innate Killer Summit 2022 in San Diego, US, from 30 March to 1 April, 2022.

31 March:
08:00 Chair’s Opening Remarks - - Kai Pinkernell
1 April:
08:45 Keynote speech: Examining Data from NK Cell Therapy to Assess Therapeutic Efficacy, and Preclinical Findings from CAR-NK Cells - Kai Pinkernell
11:00 Panel discussion: Examining Early Clinical Results & Translational Learnings - Kai Pinkernell
/11:00 Keynote speech: Conferring Stability, Consistency, and High Product Quality with Manufacturing at Scale - Volker Huppert
13:30 Panel discussion: Developing Commercial Strategy for Allogeneic Therapies - Kai Pinkernell

Glycostem CEO Troels Jordansen is going to participate the 4th Annual Cell & Gene Therapy Innovation Leaders Summit 2022, as keynote speaker, in Berlin, Germany.

Glycostem CEO Troels Jordansen and CMO Kai Pinkernell, MD, MBA to participate and give keynote speech at the Allogeneic Cell Therapies Summit Europe 2022 during 19^th-20^th January, 2022 in London, UK.

19^th Jan 2022

09:00-10:00 GMT: Keynote Panel: Achieving an Off-the-Shelf Future for Europe
17:00-17:30 GMT: Off-the-Shelf NK Cells in European AML Clinical Trial 

Glycostem to participant the 63rd ASH Annual Meeting & Exposition virtually to present abstract online, about Clinical data of the first two acute myeloid leukemia patients enrolled in the phase I/IIa WiNK clinical trial.

Title: Allogeneic, CD34+, Umbilical Cordblood-Derived NK Cell Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia Patients With Measurable Residual Disease

Session Date/Time:  11^th December 11, 2021 5:30 PM - 7:30 PM EST

Glycostem Chief Development Officer Volker Huppert to present at Next Generation Cell & Gene Therapy Conference about Scaling NK Manufacturing on 8^th Nov.
 

Glycostem to attend 8^th European Drug Discovery Strategic Summit in Amsterdam, Netherlands on 4^th & 5^th November 2021.